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Background: Platelet activity may be measured remotely as surface P-selectin 
expression. Predictors of on-treatment P-selectin expression were assessed 
using baseline characteristics in the TARDIS trial. 
 
Methods: TARDIS assessed intensive (combined aspirin, dipyridamole and 
clopidogrel, ACD) versus guideline (aspirin/dipyridamole, AD; or clopidogrel 
alone, C) antiplatelets in 3096 patients with acute stroke or TIA. On-treatment 
P-selectin levels were measured remotely at 7 days post randomisation. The 
tests detected the effects of either aspirin or clopidogrel. Analyses have been 
split by test and randomised treatment. 
 
Results: 626 patients (ACD 312, AD 142, C 172) had P-selectin taken at day 7. 
For the aspirin sensitive test, P-selectin expression was only related to prior 
antiplatelet treatment in ACD patients: those on A (mean difference, MD -69.6, 
p=0.010) or AC (MD -95.3, p=0.037) prior to randomisation had lower levels 
than those on nothing. None of the baseline characteristics had any relationship 
with P-selectin in AD patients. For the clopidogrel test, P-selectin levels were 
only related to prior antiplatelet therapy in ACD patients: patients on C had 
lower levels (MD -157.5, p=0.026), and those on AD had higher levels (MD 
210.1, p=0.0044) than those on nothing. In C patients, P-selectin was lower in 
smokers than non-smokers (MD -128.4, p=0.0048) and patients with a history 
of hypertension had higher levels (MD 83.1, p=0.036). 
 
Conclusion: In ACD patients, prior antiplatelet treatment appeared to effect on-
treatment P-selectin. In clopidogrel alone patients, P-selectin expression was 
lower in smokers than non-smokers, suggesting that smokers are less likely to 
exhibit resistance to clopidogrel. 
 
 
 
 
Word count: Title 23/25, Abstract 250 /250 
